Pharmaceutical Preparations · DE · CIK 1937653
Zymeworks develops novel biotherapeutics for difficult-to-treat diseases and manages licensed healthcare assets
Comparable business profile · signals at a glance
In the 90 days to Jan 12, 2026: 4 sold $4.7M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 12, 2026 | Galbraith KennethChair & CEO | Sell | 30,424 | $22.67 | $690K |
| Jan 12, 2026 | Moore Paul AndrewChief Scientific Officer | Sell | 9,560 | $22.67 | $217K |
| Jan 12, 2026 | Smith Jeffrey T LEVP & Chief Medical Officer | Sell | 9,310 | $22.67 | $211K |
| Jan 12, 2026 | Hollywood MarkEVP & Chief Operating Officer | Sell | 6,120 | $22.67 | $139K |
| Jan 5, 2026 | Galbraith KennethChair & CEO | Sell | 31,686 | $25.10 | $795K |
| Jan 5, 2026 | Galbraith KennethChair & CEO | Sell | 22,657 | $25.10 | $569K |
| Jan 5, 2026 | Moore Paul AndrewChief Scientific Officer | Sell | 10,821 | $25.10 | $272K |
| Jan 5, 2026 | Smith Jeffrey T LEVP & Chief Medical Officer | Sell | 10,538 | $25.10 | $265K |
| Jan 5, 2026 | Moore Paul AndrewChief Scientific Officer | Sell | 9,289 | $25.10 | $233K |
| Dec 22, 2025 | Galbraith KennethChair & CEO | Sell | 47,528 | $27.02 | $1.3M |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.